Balstilmab
PreclinicalMonoclonal antibody
Balstilmab is one of 21 small molecule programs targeting Anatomic Stage IV Breast Cancer AJCC v8. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Anatomic Stage IV Breast Cancer AJCC V8
#DrugCompanyPhaseTrials
1Herceptin
OOrganon and Co
Approved
Trastuzumab Deruxtecan
AstraZenecaPhase 3
Keytruda
Merck & Co.Phase 2
Taxol
TevaPhase 2
Adriamycin
PfizerPhase 2
Halaven
EisaiPhase 2
Leukine
SanofiPhase 2
Trodelvy
GileadPhase 2
Paraplatin
AAvyxa
Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Balstilmab. EMBL-EBI & Wellcome Sanger Institute.
- [4]